A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma Editorial

  


Authors: Ghione, P.; Palomba, M. L.; Ray, M. D.; Limbrick-Oldfield, E. H.; Owen, J.; Kanters, S.; Bobillo, S.; Ribiero, M. T.; Jacobson, C. A.; Neelapu, S. S.; Ghesquieres, H.; Nahas, M.; Beygi, S.; Patel, A. R.; Gribben, J. G.
Title: A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma
Abstract: In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population. © 2024
Keywords: non-hodgkin's lymphoma; efficacy; car t-cell; indirect treatment comparison; axi-cel
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 24
Issue: 5
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2024-05-01
Start Page: e191
End Page: e195.e6
Language: English
DOI: 10.1016/j.clml.2024.01.011
PUBMED: 38365528
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187506650&doi=10.1016%2fj.clml.2024.01.011&partnerID=40&md5=ba40d7798b65816771ae8f6b8f955dfd
Notes: Editorial -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Maria Lia Palomba
    415 Palomba
  2. Paola Ghione
    74 Ghione
Related MSK Work